{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:02:54Z","timestamp":1794333774565,"version":"4.9.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007880","name":"Johns Hopkins","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001962","name":"A-T Children&apos;s Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["RO1 FD007605"],"award-info":[{"award-number":["RO1 FD007605"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 TR003534"],"award-info":[{"award-number":["R21 TR003534"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RR00052"],"award-info":[{"award-number":["RR00052"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jaci.2024.10.023","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T01:29:30Z","timestamp":1731029370000},"page":"640-649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Prevalence and outcomes of cancer and treatment-associated toxicities for patients with ataxia telangiectasia"],"prefix":"10.1016","volume":"155","author":[{"given":"Aimee","family":"Magnarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao P.","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninad","family":"Oak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Natale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Rothblum-Oviatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen A.","family":"Lefton-Greif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"McGrath-Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Ehrhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Lederman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0462-661X","authenticated-orcid":false,"given":"Richa","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2024.10.023_bib1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/336577a0","article-title":"Localization of an ataxia-telangiectasia gene to chromosome 11q22-23","volume":"336","author":"Gatti","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2024.10.023_bib2","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41580-021-00394-2","article-title":"Cellular functions of the protein kinase ATM and their relevance to human disease","volume":"22","author":"Lee","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jaci.2024.10.023_bib3","series-title":"GeneReviews\u00ae","article-title":"Ataxia-telangiectasia","author":"Veenhuis","year":"1993"},{"key":"10.1016\/j.jaci.2024.10.023_bib4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjh.17736","article-title":"The incidence and type of cancer in patients with ataxia-telangiectasia via a retrospective single-centre study","volume":"194","author":"Bakhtiar","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2024.10.023_bib5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2011.08863.x","article-title":"Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey","volume":"155","author":"Bienemann","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2024.10.023_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.21.01495","article-title":"Cancer in children with fanconi anemia and ataxia-telangiectasia\u2014a nationwide register-based cohort study in Germany","volume":"40","author":"Dutzmann","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2024.10.023_bib7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/pbc.24696","article-title":"Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies","volume":"61","author":"Sandlund","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaci.2024.10.023_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/(SICI)1096-911X(199812)31:6<491::AID-MPO5>3.0.CO;2-B","article-title":"Treatment of lymphoid malignancies in patients with ataxia-telangiectasia","volume":"31","author":"Sandoval","year":"1998","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.jaci.2024.10.023_bib9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ejmg.2016.05.012","article-title":"Treatment of acute leukemia in children with ataxia telangiectasia (A-T)","volume":"59","author":"Schoenaker","year":"2016","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.jaci.2024.10.023_bib10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.2014.56.5101","article-title":"Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies","volume":"33","author":"Suarez","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2024.10.023_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/MPH.0000000000001005","article-title":"Ataxia telangiectasia and cancer predisposition: challenges in management","volume":"40","author":"Upadhyaya","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jaci.2024.10.023_bib12","first-page":"89","article-title":"Mortality and cancer incidence in 263 patients with ataxia-telangiectasia","volume":"77","author":"Morrell","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaci.2024.10.023_bib13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ng1837","article-title":"ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles","volume":"38","author":"Renwick","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2024.10.023_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00066","article-title":"Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women","volume":"1","author":"Kurian","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jaci.2024.10.023_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","article-title":"Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers","volume":"14","author":"Hall","year":"2021","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.jaci.2024.10.023_bib16","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1093\/hmg\/ddx368","article-title":"Rare germline variants in known melanoma susceptibility genes in familial melanoma","volume":"26","author":"Goldstein","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaci.2024.10.023_bib17","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1200\/JCO.2007.14.6613","article-title":"Risk of cancer by ATM missense mutations in the general population","volume":"26","author":"Dombernowsky","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2024.10.023_bib18","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","volume":"35","author":"Shindo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2024.10.023_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.10.023_bib20","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/ng.3342","article-title":"Loss-of-function variants in ATM confer risk of gastric cancer","volume":"47","author":"Helgason","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2024.10.023_bib21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jamaoncol.2016.5194","article-title":"Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer","volume":"3","author":"Pearlman","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaci.2024.10.023_bib22","unstructured":"Surveillance, Epidemiology, and End Results (SEER) program. SEER\u2217Stat Database: incidence\u2014SEER research data, 8 registries, November 2022 submission (1975-2020). Linked to county attributes\u2014time dependent (1990-2021) income\/rurality, 1969-2021 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2023. Available at: www.seer.cancer.gov. Accessed July 17, 2023."},{"key":"10.1016\/j.jaci.2024.10.023_bib23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.jaci.2024.10.023_bib24","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature04866","article-title":"ATM stabilizes DNA double-strand-break complexes during V(D)J recombination","volume":"442","author":"Bredemeyer","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2024.10.023_bib25","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood-2006-05-020917","article-title":"ATM deficiency disrupts Tcra locus integrity and the maturation of CD4+CD8+ thymocytes","volume":"109","author":"Matei","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2024.10.023_bib26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1101\/gad.956902","article-title":"Sensing of intermediates in V(D)J recombination by ATM","volume":"16","author":"Perkins","year":"2002","journal-title":"Genes Dev"},{"key":"10.1016\/j.jaci.2024.10.023_bib27","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1084\/jem.20041074","article-title":"Immunoglobulin class switch recombination is impaired in Atm-deficient mice","volume":"200","author":"Lumsden","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2024.10.023_bib28","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1073\/pnas.0611222104","article-title":"ATM deficiency impairs thymocyte maturation because of defective resolution of T cell receptor alpha locus coding end breaks","volume":"104","author":"Vacchio","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2024.10.023_bib29","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1007\/s10875-021-01090-8","article-title":"Simple measurement of IgA predicts immunity and mortality in ataxia-telangiectasia","volume":"41","author":"Zielen","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.023_bib30","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/jmedgenet-2018-105635","article-title":"Genotype-phenotype correlations in ataxia telangiectasia patients with ATM c.3576G>A and c.8147T>C mutations","volume":"56","author":"van Os","year":"2019","journal-title":"J Med Genet"},{"key":"10.1016\/j.jaci.2024.10.023_bib31","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood.2024024283","article-title":"ATM germline pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies","volume":"144","author":"Elitzur","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2024.10.023_bib32","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/adc.2006.094268","article-title":"Survival probability in ataxia telangiectasia","volume":"91","author":"Crawford","year":"2006","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaci.2024.10.023_bib33","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41436-021-01240-8","article-title":"Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia","volume":"23","author":"Dalmasso","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.jaci.2024.10.023_bib34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1365-2249.2008.03684.x","article-title":"Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene","volume":"153","author":"Staples","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2024.10.023_bib35","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/bjc.2011.266","article-title":"Lymphoid tumours and breast cancer in ataxia telangiectasia: substantial protective effect of residual ATM kinase activity against childhood tumours","volume":"105","author":"Reiman","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaci.2024.10.023_bib36","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jaci.2011.03.052","article-title":"Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype","volume":"128","author":"Micol","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.10.023_bib37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ajhg.2009.08.018","article-title":"Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer","volume":"85","author":"Tavtigian","year":"2009","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2024.10.023_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/humu.20805","article-title":"Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk","volume":"30","author":"Mitui","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jaci.2024.10.023_bib39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/bjc.2011.534","article-title":"Severe reaction to radiotherapy for breast cancer as the presenting feature of ataxia telangiectasia","volume":"106","author":"Byrd","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaci.2024.10.023_bib40","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ana.20139","article-title":"Adult-onset ataxia telangiectasia due to ATM 5762ins137 mutation homozygosity","volume":"55","author":"Sutton","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaci.2024.10.023_bib41","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1086\/301706","article-title":"ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer","volume":"62","author":"Stankovic","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2024.10.023_bib42","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.10.023_bib43","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1200\/JCO.21.02678","article-title":"Children\u2019s Oncology Group Trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924011679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924011679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:05:47Z","timestamp":1777475147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674924011679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0091674924011679"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2024.10.023","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and outcomes of cancer and treatment-associated toxicities for patients with ataxia telangiectasia","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2024.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}